Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.51 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.51 |
| ▸ | PTH1R | Q03431 | 3/20 | 0.50 |
| ▸ | GLP1R | P43220 | 1/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | GIPR | P48546 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 3/20 | 0.48 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159280 | 0.97 | BACE1 (0.54) | BACE1RXFP1VIPR1PTH1RGLP1R | |
| SCHEMBL30159395 | 0.96 | BACE1 (0.51) | BACE1RXFP1VIPR1PTH1RGLP1R | |
| SCHEMBL30159127 | 0.95 | RXFP1 (0.54) | BACE1RXFP1VIPR1PTH1RGLP1R | |
| SCHEMBL30159188 | 0.93 | PTH1R (0.57) | BACE1RXFP1VIPR1PTH1RGLP1R | |
| SCHEMBL30437160 | 0.93 | BACE1 (0.56) | BACE1RXFP1VIPR1PTH1RGLP1R | |
| SCHEMBL30599009 | 0.92 | PTH1R (0.55) | BACE1RXFP1VIPR1PTH1RGLP1R | |
| SCHEMBL30906349 | 0.90 | RXFP1 (0.57) | RXFP1PTH1RGLP1R | |
| SCHEMBL31232429 | 0.90 | GLP1R (0.49) | BACE1RXFP1VIPR1GLP1RGCGR | |
| SCHEMBL30432446 | 0.89 | VIPR1 (0.57) | BACE1RXFP1VIPR1PTH1RGLP1R | |
| SCHEMBL31465333 | 0.88 | VIPR1 (0.52) | RXFP1VIPR1PTH1RTLR2VIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIBRANT HOLDINGS LLC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12454771-B2 | Substrates, peptide arrays, and methods | VIBRANT HOLDINGS LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4556467-A2 | METHODS FOR ARRAY SYNTHESIS | Vibrant Holdings, LLC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-12251674-B2 | Substrates, systems, and methods for array synthesis and biomolecular analysis | VIBRANT HOLDINGS, LLC (US) | 2025-03-18 | — | — | US | disclosed |
| EP-3617219-B1 | METHODS FOR ARRAY SYNTHESIS | VIBRANT HOLDINGS LLC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20230294063-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIBRANT HOLDINGS, LLC | 2023-09-21 | — | — | US | disclosed |
| US-11565231-B2 | Substrates, peptide arrays, and methods | VIBRANT HOLDINGS, LLC (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230294063-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIP, IAPP, GIPR | BACE1 791/4885RXFP1 777/4885VIPR1 38/4885 |
| US-20260071353-A1 | SUBSTRATES, PEPTIDE ARRAYS, AND METHODS | VIP, CALCB, SPPL2B | BACE1 401/4885RXFP1 1521/4885VIPR1 207/4885 |
| US-11565231-B2 | Substrates, peptide arrays, and methods | VIP, IAPP, GIPR | BACE1 791/4885RXFP1 777/4885VIPR1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.